CG Oncology, Inc. Common stock (CGON) - Total Liabilities
Based on the latest financial reports, CG Oncology, Inc. Common stock (CGON) has total liabilities worth $38.99 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is CG Oncology, Inc. Common stock growing its equity to track the company's year-over-year net asset growth rate.
CG Oncology, Inc. Common stock - Total Liabilities Trend (2021–2025)
This chart illustrates how CG Oncology, Inc. Common stock's total liabilities have evolved over time, based on quarterly financial data.
CG Oncology, Inc. Common stock Competitors by Total Liabilities
The table below lists competitors of CG Oncology, Inc. Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YTL Corporation Bhd
KLSE:4677
|
Malaysia | RM69.98 Billion |
|
PrairieSky Royalty Ltd
TO:PSK
|
Canada | CA$630.60 Million |
|
Hubei Feilihua Quartz Glass Co Ltd
SHE:300395
|
China | CN¥1.64 Billion |
|
Hankook Tire Co.
KO:161390
|
Korea | ₩13.08 Trillion |
|
GXO Logistics Inc
NYSE:GXO
|
USA | $9.19 Billion |
|
RTL Group SA
XETRA:RRTL
|
Germany | €4.99 Billion |
|
Shan Dong Sun Paper Industry Joint Stock Co Ltd
SHE:002078
|
China | CN¥28.55 Billion |
|
Home BancShares Inc
NYSE:HOMB
|
USA | $18.59 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down CG Oncology, Inc. Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CGON company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CG Oncology, Inc. Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CG Oncology, Inc. Common stock (2021–2025)
The table below shows the annual total liabilities of CG Oncology, Inc. Common stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $38.99 Million | +82.03% |
| 2024-12-31 | $21.42 Million | +47.61% |
| 2023-12-31 | $14.51 Million | -35.71% |
| 2022-12-31 | $22.57 Million | +22.40% |
| 2021-12-31 | $18.44 Million | -- |
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more